Several biotech firms and research institutions reported breakthroughs in immuno-oncology. Cartography Biosciences secured a $67 million Series B to progress T-cell engaging bispecific antibodies targeting cancer-specific antigens, with a lead program for colorectal cancer. Genialis partnered with Cleveland Clinic utilizing AI-driven biomarkers to predict therapy responses in pancreatic cancer, enhancing precision medicine. Additionally, Innovent Biologics introduced a long-half-life monoclonal antibody targeting IL-15 for vitiligo treatment, and Alligator Bioscience developed a bispecific antibody engaging immune receptors and tumor antigens for colorectal carcinoma therapies.